Photodynamic therapy using a second generation photosensitizer, Talaporfin

Kondo, Kazuya; Miyoshi, Takanori; Fujino, Haruhiko; Takizawa, Hiromitsu; Imai, Satoshi; Kobayashi, Naoki; Kenzaki, Koichiro; Sakiyama, Shoji; Tangoku, Akira

doi:10.1016/j.pdpdt.2007.06.001

« Previous Next »Photodiagnosis and Photodynamic Therapy
Volume 4, Issue 4 , Pages 269-274, December 2007

Photodynamic therapy using a second generation photosensitizer, Talaporfin

Kazuya Kondo, MD, PhD
- Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Kuramoto-cho, Tokushima 770-8503 Japan
- Corresponding author. Tel.: +81 88 633 7143; fax: +81 88 633 7144.
Takanori Miyoshi
- Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Kuramoto-cho, Tokushima 770-8503 Japan
Haruhiko Fujino
- Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Kuramoto-cho, Tokushima 770-8503 Japan
Hiromitsu Takizawa
- Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Kuramoto-cho, Tokushima 770-8503 Japan
Satoshi Imai
- Meiji Seika Kaisha, Ltd., Tokyo, Japan
Naoki Kobayashi
- Nippon Koden Corporation, Tokyo, Japan
Koichiro Kenzaki
- Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Kuramoto-cho, Tokushima 770-8503 Japan
Shoji Sakiyama
- Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Kuramoto-cho, Tokushima 770-8503 Japan
Akira Tangoku
- Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, University of Tokushima Graduate School, Kuramoto-cho, Tokushima 770-8503 Japan

published online 03 August 2007.

Summary

Background

Photodynamic therapy (PDT) using Talaporfin is an attractive treatment for central-type early lung cancer. It was noted that some patients had altered levels of arterial oxygen saturation as indicated by pulse oximeter (SpO₂) and arterial oxygen saturation levels in blood gas analysis (SaO₂) during PDT. The present experiments were designed to provide an explanation for these findings.

Methods

The influence of Talaporfin on SpO₂ using in vitro and in vivo experiments, and clinically, was examined.

Results

Our in vitro and in vivo experiments showed a linear relationship between Talaporfin concentration in the plasma and the SpO₂ level (R=0.9957 and 0.9837). The apparent SpO₂ level decreased according to the increase of Talaporfin concentration in the plasma. In two patients with PDT, SpO₂ levels at 4–6h and 24h after Talaporfin administration were 93% and 97%, respectively.

Conclusions

Talaporfin raised blood absorbance at 660nm with a pulse oximeter. It appeared that the presence of the drug falsely decreased the level of SpO₂ since SpO₂ did not actually change.

Keywords: Talaporfin, Photodynamic therapy, Pulse oximeter, Lung cancer